Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis

Seitz, Sebastian; Barvencik, Florian; Koehne, Till; Priemel, Matthias; Pogoda, Pia; Semler, Jutta; Minne, H. W.; Pfeiffer, Mat­thias; Zustin, Jozef; Püschel, Klaus; Eulenburg, Christine zu; Schinke, Thorsten; Amling, Michael

doi:10.1007/s00198-013-2305-x

Cited by 46 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is worth noting that osteoporosis and fractures were observed in male and female patients younger than 50 years, an age group in which osteoporosis is generally very uncommon [8]. In a Swedish cross-sectional study including 16 patients with varying degrees of mastocytosis, vertebral fractures were found in 13 of 16 patients and observed different types of skeletal lesions, including both low bone mineral density (BMD) as well as increased BMD with Quantitative histomorphometry, assessment of number of osteoblasts and osteoclasts [12] Guillaume et al (2013) Cross-sectional study 45 Radiographic imaging, bone mineral density, bone turnover marker [13] Cundy et al (1987) Case report 1 Osteopenia and response to treatment with inhibition of bone resorption [14] Johansson et al (1996) Cross-sectional study 16 Bone density, bone markers and radiological features [15] Brockow et al (2005) Cross-sectional study 29 Level of interleukin-6 level reflects severity of disease [16] Theoharides et al (2002) Cross-sectional study 26 Level of interleukin-6 level reflects severity of disease and osteoporosis [17] Barete et al (2010) Cross-sectional study 75 Bone involvement assessed by X-ray and DXA [18] Rossini et al (2011) Cross-sectional study 82 Bone mineral density, bone turnover markers and fractures [19] Broesby-Olsen et al (2013) Cross-sectional study 48 KIT D816 mutation burden does not correlate to severity of bone loss in SM [20] Essential thrombocythemia and polycythemia vera Histomorphometry and micro-CT [26] Guermazi et al (1999) Review Images of radiological abnormalities in MF, incl. Osteosclerosis [27] Mellibovsky et al (2004) Case report 9 DXA, bone histomorphometry in MF [28] Diamond et al (2002) Case report and review 4 DXA, bone histomorphometry in MF [29] Farmer et al (2015) Cross-sectional study 18 Bone structure assesses by DXA, HR-pQCT, and bone turnover [30] Barosi et al (1989) Cross-sectional study …”

Section: Resultsmentioning

confidence: 97%

See 1 more Smart Citation

Bone morbidity in chronic myeloproliferative neoplasms

Farmer

Ocias

Vestergaard

et al. 2015

Expert Review of Hematology

View full text Add to dashboard Cite

Patients with the classical Philadelphia chromosome-negative chronic myeloproliferative neoplasms including essential thrombocythemia, polycythemia vera and primary myelofibrosis often suffer from comorbidities, in particular, cardiovascular diseases and thrombotic events. Apparently, there is also an increased risk of osteoporotic fractures among these patients. However, the true prevalence, mechanisms involved and therapeutic implications are not well described. In this review, we summarize what is currently known about possible associations between bone disease and chronic myeloproliferative neoplasms. Chronic inflammation has been suggested to explain the initiation of clonal development and progression in chronic myeloproliferative neoplasms. Decreased bone mineral density and enhanced fracture risk are well-known manifestations of many chronic systemic inflammatory diseases. As opposed to systemic mastocytosis (SM) where pathogenic mechanisms for bone manifestations probably involve effects of mast cell mediators on bone metabolism, the mechanisms responsible for increased fracture risk in other chronic myeloproliferative neoplasms are not known.

show abstract

Section: Resultsmentioning

confidence: 97%

“…Bone involvement, including not only osteoporosis and osteolytic lesions but also osteosclerosis, has been described in several studies of patients with SM [8, [12][13][14][15][16][17][18][19].…”

Section: Resultsmentioning

confidence: 99%

Bone morbidity in chronic myeloproliferative neoplasms

Farmer

Ocias

Vestergaard

et al. 2015

Expert Review of Hematology

View full text Add to dashboard Cite

show abstract

“…Mechanisms explaining systemic mastocytosis-associated osteoporosis are supposed to be identical in RA, possibly though a direct effect of histamine on osteoclasts [37].…”

Section: Mast Cells and Rheumatoid Arthritismentioning

confidence: 99%

Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review

et al. 2016

View full text Add to dashboard Cite

“…The histopathological substrate of all lesions of cutaneous mastocytosis is an infiltrate by MCs that can be visualized using basic dyes, such as Giemsa, toluidine blue and Astra blue. Proliferation of MCs in bone can produces osteoporosis possible associated with pathological fractures, causing pain [7]. The GI manifestations are numerous, occurring in 50-80 % of patients.…”

Section: Discussionmentioning

confidence: 99%

Systemic mastocytosis presenting with gastrointestinal, bone and skin involvement

2014

View full text Add to dashboard Cite

Ultrasonography (US) is often the first imaging study performed in patient with abdominal pain or vague symptoms related to the gastrointestinal tract. To this end, it has been demonstrated that transabdominal sonography achieves good to excellent results in potential bowel disorders; especially, if ultrasonography findings are framed in the context of clinical information. Systemic mastocytosis is not a common disease and it usually involves skin, gastrointestinal tract and bone. It results from a clonal neoplastic proliferation of abnormal mast cells and clinically it can ranges from 'asymptomatic' with normal life expectancy to 'highly aggressive'. Symptoms are caused by the release of mast cells mediators, such as histamine, and by the increase bulk of mast cells in the tissue. We present herein a case of systemic mastocytosis presenting with abdominal symptomatology due to thickened colonic involvement showed by US associated with bone and skin involvement. Keywords Cutaneous mastocytosis Á Bowel involvement Á UltrasoundRiassunto L'ecografia è spesso considerata l'indagine di primo livello nei pazienti con dolore addominale o con altra sintomatologia aspecifica del tratto gastrointestinale. A tal proposito, è stato dimostrato che l'ecografia transaddominale è in grado di raggiungere anche eccellenti risultati nello studio dei disturbi intestinali, soprattutto se inquadrata nel contesto di specifiche informazioni cliniche. La mastocitosi sistemica è una rara patologia che generalmente coinvolge cute, tratto gastrointestinale e osso. Si tratta di proliferazione neoplastica di tipo clonale di mastociti, che clinicamente può variare da una sintomatologia lieve con normale aspettativa di vita fino ad un quadro altamente aggressivo. I sintomi sono causati dal rilascio dei mediatori contenuti nei mastociti, tra i quali l'istamina, e dall'incremento dei mastociti nei tessuti. Presentiamo qui un caso di mastocitosi sistemica caratterizzato dalla comparsa di sintomatologia addominale dovuta a ispessimento del grosso intestino identificato all'esame ecografico, associato a interessamento osseo e cutaneo della patologia.

show abstract

Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis

Cited by 46 publications

References 33 publications

Bone morbidity in chronic myeloproliferative neoplasms

Bone morbidity in chronic myeloproliferative neoplasms

Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review

Systemic mastocytosis presenting with gastrointestinal, bone and skin involvement

Contact Info

Product

Resources

About